PQR514 (panPI3K/mTOR)

Indicaton

Dual PI3K/mTOR inhibitor with reduced brain penetration for use in oncology or other therapeutic areas.

Therapeutic indications

Oncology

Type of product

Small molecule

Table

Phase

Discovery

You may also be interested in

TOP-N53, TOP-V122, TOP-M119 and TOP-N44

TOPADUR has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases as chronic wounds, glaucoma, colorectal cancer, hair loss and skin aging.

Phase I started

Proclarix

Proclarix® is CE marked, intended for in vitro diagnostic use and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml.

Venofer

Anaemic Dialysis